Martin David Harp

The Loong Crystal PR IOL is designed for the treatment of myopia in adults ranging from -3.25D to -18.00D.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

A study conducted with over 77,000 individuals found that alcohol consumption increased the risk of dry eye in women.

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

A look at the biggest news and advancements in ophthalmology in 2024.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and hemiretinal vein occlusions.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

The funding will primarily support advancement of Elate Ocular through its registration-enabling phase 3 clinical trials for dry eye disease.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

Perimeter Medical Imaging AI has been leveraging the technology to improve breast cancer surgeries and reduce the number of patients requiring repeat surgery.

A PDUFA decision date of April 2, 2025 has been assigned

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary endpoints with no serious adverse events reported in either cohort.